Sugi Predict

Sugi Predict / Compounds / SCHEMBL1750249

SCHEMBL1750249

SCHEMBL1750249

CC(C)(C)OC(=O)n1ccc2ccc(O[Si](C)(C)C(C)(C)C)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.44
▸ CA1 P00915 4/20 0.44
▸ CA9 Q16790 4/20 0.44
▸ PIK3CA P42336 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ PIK3CD O00329 2/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ EGFR P00533 2/20 0.38
▸ HCK P08631 2/20 0.38
▸ SRC P12931 2/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ MTOR P42345 2/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ EPHB4 P54760 2/20 0.38
▸ PRKDC P78527 2/20 0.38
▸ PI4KB Q9UBF8 2/20 0.38
▸ TFPI2 P48307 1/20 0.38
▸ HSP90AA1 P07900 2/20 0.37
▸ HSP90AB1 P08238 2/20 0.37
▸ PIK3R1 P27986 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30777139 0.90 KDR (0.44) CA12CA1CA9PIK3CAKDR
SCHEMBL935307 0.90 KDR (0.44) CA12CA1CA9PIK3CAKDR
SCHEMBL982760 0.83 TFPI2 (0.49) TFPI2MCL1NR1H2KDM4EALDH1A1
SCHEMBL17782610 0.81 EGFR (0.40) CA12CA1CA9PIK3CAKDR
SCHEMBL1371853 0.81 ELANE (0.47) PIK3CAKDRPIK3CDABL1EGFR
SCHEMBL29830599 0.81 ELANE (0.47) PIK3CAKDRPIK3CDABL1EGFR
SCHEMBL5015441 0.80 MCL1 (0.43) CA12CA1CA9MCL1KDM4E
SCHEMBL1751204 0.80 USP14 (0.38) PIK3CAKDRPIK3CDABL1EGFR
SCHEMBL23620195 0.80 ABL1 (0.39) PIK3CAKDRPIK3CDABL1EGFR
SCHEMBL982341 0.80 KCNQ3 (0.44) PIK3CAKDRPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753743-B1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS DEUTSCHLAND (DE) 2015-03-04 — — EP disclosed
US-7968546-B2 Pyridazinone kinase inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-06-28 — — US disclosed
US-7879815-B2 inhibitors of viral polymerases such as 5'-O-[[4-chloro-5-methyl-2-(1-methylethyl)phenoxy][[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phosphinyl]-2'-C-methylcytidine, used for the treatment of hepatitis C virus infection in mammals MERCK SHARP & DOHME CORP. (US) 2011-02-01 — — US disclosed
US-20100234316-A1 Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection MSD ITALIA S.R.L. (IT) 2010-09-16 — — US disclosed
US-7709466-B2 Pyridazinone derivatives, methods for their production and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 — — US disclosed
US-20090130209-A1 Novel Pyridazinone Derivatives AVENTIS PHARMA S.A. (FR) 2009-05-21 — — US disclosed
EP-1732938-B1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2009-05-06 — — EP disclosed
US-7507734-B2 Pyridazinone derivatives AVENTIS PHARMA S.A. (FR) 2009-03-24 — — US disclosed
US-7491710-B2 Organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2009-02-17 — — US disclosed
US-20070259870-A1 Novel Pyridazinone Derivatives AVENTIS PHARMA S.A. (FR) 2007-11-08 — — US disclosed
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-19 — — US disclosed
EP-1732938-A1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS Aventis Pharma S.A. (FR) 2006-12-20 — — EP disclosed
EP-1604988-A1 Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2005-12-14 — — EP disclosed
EP-1598348-A1 Novel pyridazinone derivatives as inhibitors of CDK2 Aventis Pharma Deutschland GmbH (DE) 2005-11-23 — — EP disclosed
WO-2005058923-A1 ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-06-30 — — WO disclosed
US-20050137171-A1 Novel organophosphorus derivatives of indazoles and use thereof as medicinal products AVENTIS PHARMA S.A. (FR) 2005-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS GSK3B, GSK3A, PDXK CA12 4820/4885CA1 4610/4885CA9 4618/4885
US-20090130209-A1 Novel Pyridazinone Derivatives CDK2, CDK1, CDK20 CA12 4860/4885CA1 4558/4885CA9 4800/4885
US-20100234316-A1 Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection NSUN2, NSUN3, RNGTT CA12 4873/4885CA1 4877/4885CA9 4654/4885
US-20070259870-A1 Novel Pyridazinone Derivatives CDK2, CDK1, CDK20 CA12 4860/4885CA1 4558/4885CA9 4800/4885
US-20050137171-A1 Novel organophosphorus derivatives of indazoles and use thereof as medicinal products PPIP5K2, INPPL1, IP6K3 CA12 2875/4885CA1 2945/4885CA9 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.